Research focus will be on developing personalized therapies
Hospital for Special Surgery in New York City has received a $5.6 million grant from The Tow Foundation to establish the Hospital for Special Surgery Genomics Center. The new center will apply genomic approaches to study two autoimmune diseases, rheumatoid arthritis and systemic lupus erythematosus, with the aim of developing more effective therapies.
"Our goals are to use genomic approaches to understand the regulation and function of disease-associated genes, understand how disease-associated genetic variants contribute to disease, and identify new genes associated with autoimmune diseases," said Lionel B. Ivashkiv, M.D., associate chief scientific officer at Hospital for Special Surgery (HSS), who will serve as director of the new center. "We will use this new knowledge to develop more effective and personalized therapies."
Genomics is the study of an organism's complete set of genetic material, including gene sequence, structure and function, regulation of gene expression, and gene-environment interactions.
In the United States, rheumatoid arthritis, a crippling disease that destroys joints, affects approximately 3 million people. Lupus, a disease that can be very serious, affects joints, skin, kidneys, blood cells, brain, heart and lungs, and impacts 600,000 people in the United States. HSS is internationally known for research into these two diseases, and treats one of the world's largest populations of rheumatoid arthritis and lupus patients.
"HSS has strength in both the clinical area and the basic science area of these diseases," said Dr. Ivashkiv. "Our strength is we can have an integrated multidisciplinary approach to trying to study and understand these diseases and develop new therapies."
"We are honored that The Tow Foundation has provided a generous grant to support our continued leadership in exploring the mysteries of autoimmune disease," said Louis A. Shapiro, president and CEO of Hospital for Special Surgery. "Thanks to the Tow Foundation's gift, our scientists and physicians will offer hope to our patients with these challenging diseases."
Over the last two decades, scientists have discovered that certain proteins, including tumor necrosis factor and interleukin-6, are associated with rheumatoid arthritis and have used this knowledge to revolutionize treatments for patients. Researchers have also identified proteins associated with lupus that have advanced therapies. Basic, translational and clinical investigators at HSS have worked together and been major contributors to the progress that has been made.
The HSS Genomics Center will use genomic approaches to understand the regulation and function of the genes associated with these proteins, as well as identify new genes associated with lupus and rheumatoid arthritis. The goal is to develop more effective treatments with fewer side effects, and researchers expect to be testing new therapeutics in animal models by year four of the grant.
The new endeavor will focus on several aspects of research including epigenetics.
"We are very excited to try to understand how genes involved in lupus and rheumatoid arthritis are regulated, because it would represent a new way to drive therapy. It is called epigenetic therapy, meaning therapy targeted around how the environment controls gene expression and thus the environmental causes of disease," said Dr. Ivashkiv.
"In recent years, researchers have identified DNA sequences previously thought to be junk DNA that regulate the expression of genes. These are affected by the environment, for example by hormones or by smoking. It turns out that a lot of susceptibility to diseases falls within these regulatory regions."